Comparative effectiveness of three linezolid management strategies for peripheral neuropathy during multidrug- or rifampicin-resistant tuberculosis treatment

We did not find evidence of a substantial negative impact of immediate modification to linezolid among people who developed mild or moderate peripheral neuropathy in the first six months of an individualized regimen. Our results support the clinical practice of cautiously adjusting linezolid when needed to manage non-severe peripheral neuropathy.